Resources

3 Resources for

schering and zocor

Subscribe to this listing via:
RSS
Email

Did you mean Schering-Plough Corp. (651 results)

BNET Resources

Schering-Plough Now in the Feds' Crosshairs: Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...; Tags: ENHANCE Trial, Schering, Schering-Plough Corp., trial result, Vytorin, Zocor, Merck & Co. Inc.; Discussion threads 2008-07-10
Is Merck Hanging Schering Out to Dry on Vytorin?: Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...; Tags: ENHANCE Trial, Merck & Co. Inc., Schering, Vytorin, Zocor; Discussion threads 2008-07-07
How Pharma Stacks the Deck with Medical Journals: How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...; Tags: ENHANCE Trial, Schering, trial result, Vytorin, Zocor; Discussion threads 2008-06-18

Additional Resources

Vytorin-cancer link can't be ruled out, doctors say: MUNICH, Germany -- Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with caution until more is known, editors of a leading medical journal urged...; Articles 2008-09-03
Lack of transparency to blame for bad rap?: ON JAN. 14, Schering-Plough released preliminary results of its ENHANCE clinical trial, finding that Vytorin (Zocor/Zetia) did nothing more than generic Zocor alone to slow the progression of plaques-in the carotid arteries of a smallish number of patients with a familial form of hypercholesterolemia who had previously been on statins....; Articles 2008-05-01

Questions on Vytorin Mount: WASHINGTON -- A congressional committee investigating whether the marketers of the cholesterol drug Vytorin withheld data that would hurt sales has released new evidence that critics contend supports such suspicions. The Senate Finance Committee noted that even the researcher who led a crucial study of the drug accused Vytorin partners...; Articles 2008-04-28
Zetia, Vytorin come under fire: WASHINGTON -- Recent hearings by two Congressional committees have left critics of the makers of cholesterol drugs Vytorin and Zetia more certain than ever that the pharmaceutical companies withheld data that would hurt sales. One of those committees--the Senate finance committee--noted that even the researcher who led a...; Articles 2008-04-21
Vytorin Coverage with Leading Health Plans Revisited - See Uptake of Generic Simvastatin and Crestor Without Need for Widespread Formulary Changes: PHILADELPHIA -- According to follow-up research from Cognet-X, Inc., conducted in the first week of April, pharmacy and medical executives at leading health plans still do not foresee widespread changes in how their organizations will cover Merck/Schering-Plough's cholesterol reducer Vytorin. Among the reasons: more than three-quarters of those...; Articles 2008-04-21
Ads, research undermine Vytorin: IN THE TURMOIL swirling around the cholesterol medication Vytorin, an important message has been lost: This is not a bad drug. But its manufacturers -- Schering-Plough and Merck -- have handled its development badly, undermining confidence in the industry and a drug that could yet prove to...; Articles 2008-04-06
Ads, research undermine Vytorin: IN the turmoil swirling around the cholesterol medication Vytorin, an important message has been lost: This is not a bad drug. But its manufacturers -- Schering-Plough and Merck -- have handled its development badly, undermining confidence in the industry and a drug that could yet prove to...; Articles 2008-04-06
Monkey see, monkey ……. don't! Rather than mirror big pharma, and capitalize on their losses, we must come up with remedies that truly do what drugs cannot do: Findings from the ENHANCE Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression study showing that the cholesterol-lowering combo-drug Vytorin Zetia plus Zocor did not reverse coronary artery atherosclerosis, despite the expected lowering of LDL cholesterol, have sent shockwaves through the medical community. Cardiologists, shaking their heads in disbelief,...; Articles 2008-03-01
Girard Gibbs LLP Investigates Possible Securities Laws Violations Concerning Schering-Plough Corp., Inc: SAN FRANCISCO -- Girard Gibbs LLP (http://www.girardgibbs.com) is investigating an alleged securities fraud by Schering-Plough Corp., Inc. ("Schering-Plough") and certain of its executives between July 24, 2006 and January 14, 2008. It is alleged that Schering-Plough issued a series of material misrepresentations in its filings with the Securities...; Articles 2008-02-21
Vytorin study raises questions about Cholesterol's Import: A firestorm of bad publicity erupted over cholesterol drugs last month when an expensive combination drug proved to be no better than an older drug alone. This finding was suppressed for 20 months by Merck and Schering-Plough, the two companies that make Vytorin, which is a one-pill combination of Zetia...; Articles 2008-02-01
FDA issues early communication about ongoing review of Vytorin: FDA issued an Early Communication Jan. 25 r garding the agency's ongoing review of Vytorin based on preliminary results from a recently completed study on this cholesterol-lowering drug. Vytorin contains both Zetia ezetimibe and Zocor simvastatin in one tablet. The ENHANCE trial tested Vytorin among patients with a...; Articles 2008-01-29
FDA Issues Early Communication about an Ongoing Review of Vytorin.: M2 PRESSWIRE-28 January 2008-US Food and Drug Administration: FDA Issues Early Communication about an Ongoing Review of VytorinC1994-2008 M2 COMMUNICATIONS LTD RDATE:25012008 The U.S. Food and Drug Administration today issued an Early Communication regarding the agency's ongoing review of...; Articles 2008-01-28
Drug trials under pressure: On the eve of a date with congressional investigators, executives from Merck and Schering-Plough acknowledged Monday that their blockbuster cholesterol drug, Vytorin, offered no benefit over Zocor. The news that Vytorin fell short of an old stand-by statin drug, now sold as a cheap generic, sent worried patients...; Articles 2008-01-17
Cholesterol-lowering drug Vytorin comes up short vs. statin in study: A controversial trial of the popular and costly cholesterol-lowering drug Vytorin showed that it offered no benefit over an older drug available in generic form, Merck and Schering-Plough said Monday. The results come from a study of 720 patients that pitted Vytorin, a drug duo made of Zetia...; Articles 2008-01-15
Data about Zetia risks was not fully revealed by Merck and Schering-Plough, evidence suggests: Merck and Schering-Plough have conducted several studies of their popular cholesterol medicine Zetia that raise questions about its risks to the liver, but the companies have never published those results, according to a "New York Times" article of Dec. 21. Partial results of the studies, alluded to in...; Articles 2008-01-15
Building on a Rival's Drug: Battling over the $32 billion cholesterol-drug market, Merck & Co. Inc. said yesterday that it planned to develop a new treatment made partly from a rival drug, Lipitor, currently produced by Pfizer Inc. Merck and its joint-venture partner, Schering-Plough Corp., said the companies aimed to market the new combination drug...; Articles 2007-03-27
Success from two sources: For cholesterol drug Vytorin, success has come in pairs. A dual mechanism of action, a harmonious partnership between Merck and Schering-Plough, and twin-themed creative combined to help Vytorin more than double growth last year. Since its launch in 2004, Vytorin has become the fastest growing product in the highly...; Articles 2007-01-01

<< Previous
page 1 of 1
Next >>

Resources

schering and zocor

BNET Resources

Additional Resources

Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors